Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high216.90 28/02/17
52 week low117.00 16/09/16
52 week change 33.00 (19.64%)
4 week volume532,701 02/03/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Ergomed revenues up 30%

Ergomed's revenues rose by 30% to 39.2 million in the year to the end of December and gross profit increased by 43% to 12...

Ergomed revenues up

Unaudited Preliminary Results for 2016

RNS Number: 6771A Ergomed plc 28 March 2017 PRESS RELEASE EMBARGOED FOR RELEASE 7.00am 28 MARCH 2017 Unaudited Preliminary Results for the year ended 31 December 2016 Top line revenue growth of 30% Gross profit up 43% New business won in 2016 increased 50% to 42 million Contracted backlog at 1 January 2017 of 70 million Multiple co...

Notice of Preliminary Results

RNS Number: 0086A Ergomed plc 21 March 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed plc Notice of Preliminary Results London, UK - 21 March 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, will ann...

Ergomed initiates study of Peprostat

Ergomed has announced the initiation of a phase IIb proof-of-concept study for Peprostat, a highly innovative treatment f...

Initiates Phase II Study of Topical PeproStat

RNS Number: 8672Z Ergomed plc 20 March 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed Initiates Phase II study of topical PeproStat in Intraoperative surgical haemostatis Headline data expected in Q1 2018 British company's invention for surgical bleeding advances in clinical development London, UK - 20 March 2017: Ergomed plc (LSE: ERGO) ...

Ergomed notes partner's successful financing round

Ergomed has noted that its co-development partner Modus Therapeutics has announced a successful financing round, rais...

Modus Therapeutics Raises SEK 32 Million

RNS Number: 2443X Ergomed plc 20 February 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed notes co-development partner Modus Therapeutics successfully raises SEK 32 million (2.9m) London, UK - 20 February 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the phar...

Fundamental DataMore

P/E ratio37.222
EPS5.4
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed Plc
25/01/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. The recent period end update for Ergomed confirmed...
equity development
Ergomed Plc
15/12/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...
equity development
Ergomed Plc
11/10/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...

Latest discussion posts More

  • Results webinar

    If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at ...
    22-Mar-2017
    equity_dev
  • See management present

    If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...
    17-Jan-2017
    equity_dev
  • Webinar with management

    We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...
    26-Sep-2016
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
GVC HLDGS30%
LLOYDS GRP.30%
FEVERTREE DRK30%
GEMFIELDS30%
INDIVIOR30%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO